Yokogawa Holdings Corporation has invested in TwoCells and MedRhythms through the JGC MIRAI Innovation Fund, aiming to innovate in regenerative medicine and digital therapeutics to address Japan's healthcare challenges.

Information on the Target

Yokogawa Holdings Corporation, under the leadership of CEO Masayuki Sato, has announced an investment through the JGC MIRAI Innovation Fund, a corporate venture capital fund co-managed with JGC Corporation. This investment targets two firms specializing in mesenchymal stem cell (MSC) regenerative medicine and digital therapeutics. The two invested companies are TwoCells, located in Hiroshima, Japan, and MedRhythms Inc., based in Maine, USA.

TwoCells focuses on developing high-quality MSC products through proprietary cultivation technologies, notably their gMSC® product, which is currently undergoing Phase III clinical trials. MedRhythms, on the other hand, offers innovative digital therapeutic solutions for stroke patients experiencing walking disorders, utilizing a unique music therapy model that has received Breakthrough Device designation from the U.S. FDA.

Industry Overview in Japan

Japan is facing significant societal challenges such as population decline and an aging populace, which necessitates the development of innovative solutions in healthcare